PharmaMar begins pivotal study of plitidepsin to treat angioimmunoblastic T-cell lymphoma

Spanish-based biopharmaceutical company PharmaMar has commenced the multicentre, prospective, pivotal study to assess the efficacy of anti-cancer agent plitidepsin in patients with relapsed and refractory angioimmunoblastic T-cell lymphoma.
Source: Drug Development Technology - Category: Pharmaceuticals Source Type: news